OX40 monoclonal antibody (Beijng Immunoah Pharma Tech)

N/A

Report date: 2024/07/12 11:59:37

Base Information

Drug NameOX40 monoclonal antibody (Beijng Immunoah Pharma Tech)
Drug Alias NameOX40 Mab (Beijng Immunoah Pharma Tech)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 modulators
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijng Immunoah Pharma Tech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijng Immunoah Pharma Tech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A